Pilot Evaluation of the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Women with Hair Loss
Main Article Content
Keywords
Female pattern hair loss, Nutraceuticals, Non-scarring alopecia, Hair density, Phototrichogram, Canfield HairMetrix, Scarring alopecia, Gummy supplement
Abstract
Background: Hair loss in women is a prevalent condition with significant psychosocial impact, yet therapeutic options remain limited. Nutraceutical supplements are widely used as adjunctive therapy; however, few formulations—particularly gummy-based delivery formats designed to improve adherence—have been evaluated using objective imaging endpoints.
Methods: This prospective, single-center, single-arm pilot study evaluated the safety and efficacy of Xtressé™, a dermatologist-developed gummy nutraceutical, in 24 women with self-perceived hair thinning. Participants consumed two gummies daily for four months. Seventeen participants (11 non-scarring alopecia, 6 scarring alopecia) completed the study. Primary outcomes included change in hair density by Canfield HairMetrix® phototrichogram analysis and change in global alopecia severity by SOCAi Vision™.
Results: Among participants with non-scarring alopecia, 81.8% met responder criteria by Canfield HairMetrix® phototrichogram analysis, with mean increases in total hair density (+7.35%, 11.4 hairs/cm²) and terminal hair density (+6.81%, 10.2 hairs/cm²); 63.6% also demonstrated improvement in global scalp coverage by SOCAi Vision™. Among participants with scarring alopecia, localized phototrichogram parameters within scarred regions of interest declined (16.7% responder rate by Canfield), consistent with irreversible follicular loss, whereas global imaging detected improvement in surrounding non-scarred scalp in 66.7% by SOCAi Vision™. Mean relative improvement in global coverage exceeded 20% among SOCAi responders in both subgroups. No adverse events were reported.
Conclusion: Xtressé™ was safe, well tolerated, and associated with measurable improvements in hair parameters among women with non-scarring alopecia. These findings support the potential role of multi-ingredient nutraceutical therapy as adjunctive treatment for hair loss. Larger, controlled trials are warranted.
References
2. Dlova NC, Fabbrocini G, Lauro C, Spano M, Tosti A, Hift RJ. Quality of life in South African Black women with alopecia: a pilot study. Int J Dermatol. 2016;55(8):875-881.
3. Trüeb RM. Oxidative stress in ageing of hair. Int J Trichology. 2009;1(1):6-14.
4. Drake L, Reyes-Hadsall S, Martinez J, Heinrich C, Huang K, Barbieri JS. Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review. JAMA Dermatol. 2023;159(1):79-86.
5. Ablon G. A 3-month, randomized, double-blind, placebo-controlled study evaluating the ability of an extra-strength marine protein supplement to promote hair growth and decrease shedding in women with self-perceived thinning hair. Dermatol Res Pract. 2015;2015:841570.
6. Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558-565.
7. Gudobba C, Ezaldein HH, Scott JF, Bordone LA. Automating hair loss labels for universally scoring alopecia from images: rethinking alopecia scores. JAMA Dermatol. 2023;159(2):143-150.
8. Sacha JP, Schaefer R, Batchelor D, Gale F, Sherwood O, Sherrill J. Machine learning algorithm for automated hair counting and analysis. Int J Cosmet Sci. 2021;43(S1):S34-S41.
